Clinical trial

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

NCT01673867

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-11-02

PhasePHASE3

Study timeline

Study start (actual)2012-11-02Date precision: day

Registry last updated2023-02-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Squamous Cell Non-small Cell Lung Cancerunresolved

Interventions

NivolumabBIOLOGICAL

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

Bristol-Myers Squibblead sponsor

Mapped research locations

BostonMassachusetts, United States3 MoscowRussia3 NashvilleTennessee, United States2 MadridSpain2 SeattleWashington, United States2 SingaporeSingapore2 Porto AlegreRio Grande do Sul, Brazil2 Hong KongHong Kong2 LimaPeru2 Mexico CityMexico City, Mexico2 New YorkNew York, United States1 HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01673867 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.